PMV Pharmaceuticals (PMVP) Corporate presentation summary

Rezatapopt and target

• Oral, first-in-class investigational small molecule designed to selectively bind and stabilize mutant p53 Y220C, restoring wild-type conformation and tumor-suppressor function.

• TP53 Y220C occurs in ~1% of solid tumors and 3.2% of ovarian cancers; estimated 2L+ U.S. and EU4/UK addressable population is ~14,000 across tumors.

Clinical efficacy

• Phase 2 PYNNACLE interim data across cohorts showed 34% ORR and median DoR of 7.6 months; all five unconfirmed PRs at the Sep. 4, 2025 cutoff later became confirmed PRs.

• Ovarian cohort data showed 46% ORR and median DoR of 10 months; response rate was reported across heavily pretreated patients, with 96% platinum-resistant or refractory and 78% with ≥3 prior therapy lines.

• At the May 14, 2026 cutoff, ovarian ORR was 46% (95% CI: 34.5%-57.9%) in 76 patients; median DoR was 10.0 months, with responses deepening through PR-to-CR conversions.

• Ovarian median time to response was 1.3 months; ~40% remained on treatment, and median DoR was 8.2 months at the Mar. 29, 2026 cutoff.

Safety and study design

• In the 141-patient safety population, common treatment-related adverse events included nausea (41.8%), fatigue (25.5%) and increased blood creatinine (22.0%); 7 patients (5.0%) discontinued due to TRAEs, with no Grade 5 TRAEs.

• Phase 2 PYNNACLE is actively enrolling across ~70 sites; the ~200-patient study uses rezatapopt 2,000 mg once daily with food and evaluates ORR, response duration, PFS, OS and safety.